Lytix Biopharma Investor Relations Material
Latest events
Q4 2024
Lytix Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lytix Biopharma
Access all reports
Segment Data
Access more data
Operating income by
Geography
U.S.
Norway
Expenses by
Financials
Lytix Biopharma is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company specializes in using oncolytic peptides, which are designed to kill cancer cells and stimulate the immune system to generate a strong, systemic T-cell response. This approach aims to overcome the challenges of tumor heterogeneity, where variations in cancer cells within a tumor reduce the effectiveness of conventional immunotherapies. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Lytix Biopharma
Q2 2024
Lytix Biopharma
Q2 2024
Lytix Biopharma
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
LYTIX
Country
🇳🇴 Norway